{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:33:20Z","timestamp":1790609600714,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaacapopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAACAP Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaacop.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T21:03:56Z","timestamp":1716757436000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5826-1588","authenticated-orcid":false,"given":"Sarah D.","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3310-3439","authenticated-orcid":false,"given":"Nanco","family":"Hefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-7397","authenticated-orcid":false,"given":"Caroline","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaacop.2024.04.005_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jaacop.2024.04.005_bib2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaacop.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1192\/bjp.bp.108.060723","article-title":"Age at onset and cognition in schizophrenia: meta-analysis","volume":"195","author":"Rajji","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ajp.2019.05.031","article-title":"A comparative study of childhood\/adolescent and adult onset schizophrenia: does the neurocognitive and psychosocial outcome differ?","volume":"43","author":"Grover","year":"2019","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.jaacop.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1176\/appi.ajp.157.10.1652","article-title":"Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity","volume":"157","author":"Hollis","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/oxfordjournals.schbul.a033495","article-title":"The psychosocial outcome of adolescent-onset schizophrenia: a 12-year followup","volume":"26","author":"Lay","year":"2000","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaacop.2024.04.005_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00004583-200302000-00011","article-title":"Adult outcome of social function in adolescent-onset schizophrenia and affective psychosis","volume":"42","author":"Jarbin","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.11.018","article-title":"Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study","volume":"152","author":"Fraguas","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaacop.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1192\/bjp.2019.161","article-title":"Ten-year employment patterns of patients with first-episode schizophrenia-spectrum disorders: comparison of early intervention and standard care services","volume":"217","author":"Chan","year":"2020","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","article-title":"Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis","volume":"56","author":"Pagsberg","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0000000000001506","article-title":"Comparative efficacy and tolerability of antipsychotics for juvenile psychotic disorders: a systematic review and network meta-analysis","volume":"42","author":"Yee","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0706743717720197","article-title":"Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth","volume":"62","author":"Abidi","year":"2017","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/schbul\/sbq172","article-title":"Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia","volume":"38","author":"Olfson","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaacop.2024.04.005_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117166","article-title":"Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis","volume":"10","author":"Stafford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaacop.2024.04.005_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.chc.2019.08.009","article-title":"Psychopharmacologic treatment of schizophrenia in adolescents and children","volume":"29","author":"Lee","year":"2020","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.jaacop.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaacop.2024.04.005_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled Phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaacop.2024.04.005_bib25","first-page":"11","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","article-title":"A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia","volume":"21","author":"Forbes","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2464","article-title":"Exposure\u2013response modeling in adults and adolescents with schizophrenia to support the extrapolation of brexpiprazole efficacy to adolescents","author":"Wang","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/jcph.2307","article-title":"Population pharmacokinetic analysis of brexpiprazole to support its indication and dose selection in adolescents with schizophrenia","volume":"63","author":"Wang","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib29","series-title":"K-SADS-PL DSM-5","author":"Kaufman","year":"2016"},{"key":"10.1016\/j.jaacop.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jaacop.2024.04.005_bib31","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaacop.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia\u2013Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaacop.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"A children\u2019s global assessment scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib38","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMoa031049","article-title":"Obesity and the metabolic syndrome in children and adolescents","volume":"350","author":"Weiss","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaacop.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaacop.2024.04.005_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","article-title":"Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia","volume":"174","author":"Kane","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaacop.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/pcn.12654","article-title":"Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study","volume":"72","author":"Ishigooka","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jaacop.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1017\/S2045796019000313","article-title":"Prevalence of suicide attempts in individuals with schizophrenia: a meta-analysis of observational studies","volume":"29","author":"Lu","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.jaacop.2024.04.005_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JCP.0000000000000979","article-title":"Effect of brexpiprazole on prolactin: an analysis of short- and long-term studies in schizophrenia","volume":"39","author":"Ivkovic","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib47","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/03007995.2018.1498779","article-title":"Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of Phase 3 clinical studies","volume":"34","author":"Newcomer","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaacop.2024.04.005_bib48","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"8","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaacop.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaacop.2024.04.005_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200507000-00003","article-title":"Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder","volume":"20","author":"Ciliberto","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jaacop.2024.04.005_bib51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1471-244X-10-89","article-title":"Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder","volume":"10","author":"Stauffer","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jaacop.2024.04.005_bib52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1176\/appi.ps.002412012","article-title":"Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study","volume":"64","author":"Arnold","year":"2013","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaacop.2024.04.005_bib53","article-title":"Eliciting adverse effects data from participants in clinical trials","volume":"1","author":"Allen","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["JAACAP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949732924000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949732924000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:05:32Z","timestamp":1762650332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949732924000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2949732924000437"],"URL":"https:\/\/doi.org\/10.1016\/j.jaacop.2024.04.005","relation":{},"ISSN":["2949-7329"],"issn-type":[{"value":"2949-7329","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study","name":"articletitle","label":"Article Title"},{"value":"JAACAP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaacop.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Academy of Child & Adolescent Psychiatry.","name":"copyright","label":"Copyright"}]}}